Jeremy Kane, Ph.D.

Headshot of a man with short hair, wearing glasses.

Contact Information

Summary

Jeremy Kane, Ph.D., is originally from Thousand Oaks, California. He received a Bachelor of Science in Biotechnology from the Rochester Institute of Technology in Rochester, New York, in 2019. After working for 2 years as a technician at Cornell and Roswell Park Cancer Institute, he was accepted into the Cancer Biology Graduate Program at Vanderbilt University, where he completed his Ph.D. under the mentorship of Dr. Rachelle Johnson. After finishing his Ph.D. in 2026, Dr. Kane accepted a postdoctoral fellowship at NIAMS, where he works under the mentorship of Dr. Tamara Alliston.

Research Statement

Dr. Kane’s research focuses on osteocyte signaling and its regulation of bone mass and bone quality. His particular focus is on mitochondrial and metabolic genes that regulate osteocyte extracellular matrix. Dr. Kane is also broadly interested in how signaling between bone cells maintains bone homeostasis and how this affects bone anabolism and catabolism, particularly in the context of bone metastatic cancers.

Scientific Publications

Programmed cell death ligand 1 (PD-L1) inhibition in tumor naïve mice is bone-sparing throughout the lifespan.

Searcy MB, Joseph GJ, Kane JF, Challa L, Tanaka H, Uppuganti S, Smith JA, Rosenthal EL, Harrison DG, Nyman JS, Weivoda MM, Johnson RW
J Bone Miner Res.
2026 Jul 9;
pii: zjag104. doi: 10.1093/jbmr/zjag104
PMID: 42424413

Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer.

Miller JS, Kane JF, Ward PA, Shawkey M, Watkins A, Johnson RW, Rhoades JA
J Bone Oncol.
2026 Apr;
57().
doi: 10.1016/j.jbo.2026.100752
PMID: 41798079

Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner.

Joseph GJ, Vecchi Iii LA, Uppuganti S, Kane JF, Durdan M, Hill P, McAdoo AG, Tanaka H, Kell D, Searcy MB, Chen W, Rosenthal EL, Harrison DG, Nyman JS, Weivoda MM, Johnson RW
J Bone Miner Res.
2025 Jul 28;
40(8).
doi: 10.1093/jbmr/zjaf055
PMID: 40318222

Abaloparatide increases bone mass without affecting growth of bone-disseminated cancer cells.

Kane JF, Joseph GJ, Vecchi LA 3rd, Miller JS, Ludington BT, Gibson-Corley KN, Johnson RW
JBMR Plus.
2025 Jul;
9(7).
doi: 10.1093/jbmrpl/ziaf080
PMID: 40584157

PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.

Edwards CM, Kane JF, Smith JA, Grant DM, Johnson JA, Diaz MAH, Vecchi LA 3rd, Bracey KM, Omokehinde TN, Fontana JR, Karno BA, Scott HT, Vogel CJ, Lowery JW, Martin TJ, Johnson RW
Breast Cancer Res.
2024 Feb 26;
26(1).
doi: 10.1186/s13058-024-01791-z
PMID: 38409028

Re-Evaluating the Role of PTHrP in Breast Cancer.

Kane JF, Johnson RW
Cancers (Basel).
2023 May 9;
15(10).
doi: 10.3390/cancers15102670
PMID: 37345007

Education

Vanderbilt University 
Ph.D. in Cancer Biology (2021-2026)

Rochester Institute of Technology 
B.S. in Biotechnology and Molecular Biosciences (2015-2019) 

Experience

Postdoctoral Fellow 
NIAMS (2026-Present) 

Research Technologist 
Roswell Park Cancer Institute (2019-2021) 

Field Technician 
Cornell University (2019)

Last Updated: